文献速递肝病消化道肿瘤与早癌

在代谢功能障碍相关脂肪性肝病中启动肝细胞癌监测的无创检测的成本-效用分析

Cost-Utility Analysis of Noninvasive Tests to Initiate Hepatocellular Carcinoma Surveillance in Metabolic Dysfunction-Associated Steatotic Liver Disease.
PubMed 文献 · Am J Gastroenterol · 2025-01-29

本研究采用马尔可夫模型进行成本-效用分析,比较不使用无创检测与三种无创检测策略(FIB-4联合VCTE、单用FIB-4、单用VCTE)在四类MASLD人群中识别晚期肝纤维化并启动每半年一次超声联合甲胎蛋白监测肝细胞癌的成本效果。结果显示FIB-4联合VCTE在所有组中增量成本效果比最低,是最具成本效果的策略。

要点

  • FIB-4联合VCTE在所有MASLD人群中增量成本效果比最低,最具成本效果。
  • 美国一般MASLD人群中FIB-4联合VCTE和单用FIB-4均有成本效果,泰国仅FIB-4联合VCTE有成本效果。
  • BMI>30的MASLD患者中美国所有策略均有成本效果,泰国仅FIB-4联合VCTE有成本效果。

核心结论

  • 使用FIB-4联合VCTE启动肝细胞癌监测对MASLD患者具有成本效果。
  • 若无VCTE,单用FIB-4是合并糖尿病或3项代谢特征的MASLD患者的成本效果替代方案。

研究设计与样本

  • 成本-效用分析,采用马尔可夫模型,比较不使用无创检测与三种无创检测策略(FIB-4联合VCTE、单用FIB-4、单用VCTE)识别晚期肝纤维化并启动每半年一次超声联合甲胎蛋白监测肝细胞癌。
  • 分析人群为四类MASLD患者:一般MASLD患者、BMI>30 kg/m²的MASLD患者、合并糖尿病的MASLD患者、合并3项代谢特征(糖尿病、高血压和BMI>30)的MASLD患者。

主要发现

  • FIB-4联合VCTE在所有组中增量成本效果比最低,其次为单用FIB-4和单用VCTE。
  • 一般MASLD人群中,美国FIB-4联合VCTE和单用FIB-4均有成本效果,泰国仅FIB-4联合VCTE有成本效果。
  • BMI>30的MASLD患者中,美国所有策略均有成本效果,泰国仅FIB-4联合VCTE有成本效果。
  • 合并糖尿病或3项代谢特征的MASLD患者中,美国所有策略均有成本效果,泰国FIB-4联合VCTE和单用FIB-4有成本效果。

关键数值与推荐

  • FIB-4联合VCTE在所有组中增量成本效果比最低。
  • 一般MASLD人群:美国FIB-4联合VCTE和单用FIB-4有成本效果,泰国仅FIB-4联合VCTE有成本效果。
  • BMI>30的MASLD患者:美国所有策略有成本效果,泰国仅FIB-4联合VCTE有成本效果。
  • 合并糖尿病或3项代谢特征的MASLD患者:美国所有策略有成本效果,泰国FIB-4联合VCTE和单用FIB-4有成本效果。

临床怎么用

  • 作者认为使用FIB-4联合VCTE启动肝细胞癌监测对MASLD患者具有成本效果。
  • 作者认为若无VCTE,单用FIB-4是合并糖尿病或3项代谢特征的MASLD患者的成本效果替代方案。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Noninvasive tests (NITs), e.g., Fibrosis-4 Index (FIB-4) and vibration-controlled elastography (VCTE), have been used to identify patients with metabolic dysfunction-associated steatotic liver disease (MASLD) at high risks for hepatocellular carcinoma (HCC). This study investigates the cost-effectiveness of NITs to identify MASLD patients with advanced liver fibrosis and initiate HCC surveillance. METHODS: A cost-utility analysis using a Markov model compared no use of NITs with 3 NIT strategies: (i) FIB-4 and VCTE (FIB-4/VCTE), (ii) FIB-4 alone, and (iii) VCTE alone to identify advanced liver fibrosis and initiate HCC surveillance with biannual ultrasonography with alpha-fetoprotein in 4 MASLD populations: (i) general patients with MASLD, (ii) MASLD patients with body mass index (BMI) > 30 kg/m 2 , (iii) MASLD patients with diabetes, and (iv) MASLD patients with 3 metabolic traits (diabetes, hypertension, and BMI >30). RESULTS: FIB-4/VCTE was the most cost-effective approach across all groups, showing the lowest incremental cost-effectiveness ratio, followed by FIB-4 alone and VCTE alone. In the general MASLD population, both FIB-4/VCTE and FIB-4 alone were cost-effective in the United States, whereas only FIB-4/VCTE was cost-effective in Thailand. For MASLD patients with BMI >30, all strategies were cost-effective in the United States, whereas only FIB-4/VCTE was cost-effective in Thailand. In MASLD patients with diabetes or 3 metabolic traits, all strategies were cost-effective in the United States, whereas FIB-4/VCTE and FIB-4 alone were cost-effective in Thailand. DISCUSSION: Using FIB-4/VCTE to initiate HCC surveillance is cost-effective for patients with MASLD. If VCTE is unavailable, FIB-4 alone is a cost-effective alternative for MASLD patients with diabetes or 3 metabolic traits.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Decharatanachart P, Poovorawan K, Tangkijvanich P, et al. Cost-Utility Analysis of Noninvasive Tests to Initiate Hepatocellular Carcinoma Surveillance in Metabolic Dysfunction-Associated Steatotic Liver Disease. Am J Gastroenterol. 2025. PMID: 39878449. doi:10.14309/ajg.0000000000003332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。